PP
RNAM

PDT Partners’s Avidity Biosciences RNAM Stock Holding History

PDT Partners’s Portfolio RNAM Stock Details RNAM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-38,846
Closed -$1.78M – 811
2024
Q3 		$1.78M Sell
38,846
-9
-0% -$391 0.16% 236
2024
Q2 		$1.59M Sell
38,855
-84,176
-68% -$2.42M 0.15% 244
2024
Q1 		$3.14M Buy
123,031
+31,431
+34% +$493K 0.3% 105
2023
Q4 		$829K Buy
+91,600
New +$612K 0.09% 317
2023
Q1 		– Sell
-70,032
Closed -$1.55M – 694
2022
Q4 		$1.55M Buy
+70,032
New +$1.04M 0.25% 134
2022
Q2 		– Sell
-33,198
Closed -$613K – 1128
2022
Q1 		$613K Sell
33,198
-4,016
-11% -$68.2K 0.05% 524
2021
Q4 		$885K Buy
37,214
+2,814
+8% +$67.2K 0.07% 395
2021
Q3 		$847K Buy
34,400
+6,500
+23% +$141K 0.06% 376
2021
Q2 		$689K Buy
+27,900
New +$649K 0.05% 448

Other funds holding RNAM

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

PDT Partners's RNAM Position: Q4 2024 in Review

PDT Partners sold out of Avidity Biosciences (RNAM) in Q4 2024, closing a stake of 38,846 shares — an estimated $1.78M sold.

PDT Partners first reported a position in RNAM in Q2 2021 and held it in 9 quarters. The position peaked at $3.14M in Q1 2024. 236 funds tracked by Wall St. Rank hold RNAM as of Q4 2024.

  • PDT Partners reported no remaining Avidity Biosciences position as of Q4 2024 after selling out during the quarter.
  • PDT Partners sold 38,846 Avidity Biosciences shares in Q4 2024, an estimated $1.78M.
  • PDT Partners first reported a position in Avidity Biosciences in Q2 2021 and held it in 9 quarters.
  • PDT Partners's Avidity Biosciences position peaked at $3.14M in Q1 2024.
  • 236 funds tracked by Wall St. Rank held Avidity Biosciences as of Q4 2024.

Based on PDT Partners's 13F filing for Q4 2024, filed 14 Feb 2025.